Diamyd implements rights issue of approximately MSEK 21 to fund expanded diabetes portfolio
Not for release, publication or distribution, directly or indirectly, in the United States, Canada, Japan, Australia, New Zealand or South Africa. Diamyd Medical recently concluded a new exclusive licensing agreement relating to the therapeutic use of GABA for the treatment of diabetes and other inflammation-related conditions. In order to finance the development of the new rights, the Board of Directors of Diamyd Medical, with the support of the mandate granted, has decided to implement a share issue in an amount of MSEK 20.7 with preferential rights for Diamyd Medical’s shareholders (